AbbVie — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)inJia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersAlexandria+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.